상세 보기
- Modi, Shanu;
- Jacot, William;
- Iwata, Hiroji;
- Park, Yeon Hee;
- Vidal Losada, Maria;
- 외 20명
WEB OF SCIENCE
14SCOPUS
15초록
In DESTINY-Breast04 (NCT03734029), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician's choice of chemotherapy (TPC) for patients with human epidermal growth factor receptor 2-low (HER2-low) (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative) metastatic breast cancer. After an extended median follow-up of 32.0 months, median OS in the overall cohort was 22.9 months for T-DXd and 16.8 months for TPC (hazard ratio 0.69; 95% confidence interval 0.55-0.86). For the hormone receptor-positive cohort, median OS was 23.9 and 17.6 months for T-DXd and TPC, respectively (hazard ratio 0.69; 95% confidence interval 0.55-0.87). Median OS also favored T-DXd in exploratory analyses of hormone receptor-negative, estrogen receptor IHC 1%-10% and estrogen receptor IHC >10% cohorts. The overall safety profile of T-DXd was acceptable and generally manageable. Results confirm T-DXd as standard of care after prior chemotherapy in patients with HER2-low metastatic breast cancer. ClinicalTrials.gov identifier: NCT03734029.
키워드
- 제목
- Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
- 저자
- Modi, Shanu; Jacot, William; Iwata, Hiroji; Park, Yeon Hee; Vidal Losada, Maria; Li, Wei; Tsurutani, Junji; Ueno, Naoto T.; Zaman, Khalil; Prat, Aleix; Papazisis, Konstantinos; Rugo, Hope S.; Yamashita, Toshinari; Harbeck, Nadia; Im, Seock-Ah; De Laurentiis, Michelino; Pierga, Jean-Yves; Wang, Xiaojia; Gombos, Andrea; Tokunaga, Eriko; Aguilar, Cecilia Orbegoso; Yung, Lotus; Xiao, Feng; Cheng, Yingkai; Cameron, David
- 발행일
- 2025-10
- 유형
- Article; Early Access
- 저널명
- Nature Medicine
- 권
- 31
- 호
- 12